We previously reported that iron accumulates in NAFLD patients and in in vitro and in vivo NAFLD models and that recombinant fibroblast growth factor 21 (FGF21) ameliorates NAFLD by attenuating HIO [14]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.